Page 73 - Demo

CUAJ %u2022 AUGUST 2025 %u2022 VOLUME 19, ISSUE 8 Optimizing therapy for high-risk BCR non-metastatic PCaCOMPETING INTERESTS: Dr. Kollmannsberger has participated in advisory boards for AbbVie, Astellas, Bayer, BMS, BionTech, Eisai, Ipsen, Janssen, Merck, Novartis, and Pfizer; has received honoraria for presentations from AbbVie, Astellas, Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Novartis, and Pfizer; and has been a PI or co-PI for clinical trials supported by AbbVie, Astellas, Bayer, BMS, BionTech, Eisai, Ipsen, Janssen, Merck, Novartis, Pfizer, and Roche. Dr. Loblaw has participated in advisory boards for and received honoraria/consulting fees from Astellas, Bayer, J&J, Knight, Sumitomo, Tersera, and Tolmar; has received grants from Astellas, Tersera, and Tolmar; and holds a leadership position with Cure Prostate Cancer Canada Foundation. Dr. Pouliot has participated in advisory boards for Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Pfizer, Roche, Tersera, and Tolmar; has received honoraria from Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Pfizer, Roche, Tersera, and Tolmar; holds investments in Allogene Therapeutics; and is on the boards of the U.S. National Cancer Institute (NCI) Prostate Cancer Task Force, Canadian Urologic Oncology Group, and the GU Trial Development Group-Canadian Clinical Trial Group (CCTG). Dr. Rendon has participated in advisory boards for, is a speakers%u2019 bureau member for, and has received honoraria from AbbVie, Amgen, Astellas, Astra Zeneca, Bayer, BMS, EMD Serono, Ferring, Jansen, McKesson, Pfizer, Tersera, and Tolmar; has received honoraria/grants from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, McKesson, Pfizer, Tersera, and Tolmar; holds investments in Myovant; and has participated in clinical trials supported by AAA/Novartis, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Myovant, Pfizer, and Point Biopharma. Dr. Saad has participated in advisory boards for and has received payment/honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis, Pfizer, Tersera, and Tolmar; and has participated in clinical trials supported by AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, ESSA, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Tersera, and Tolmar. The remaining authors do not report any competing personal or financial interests related to this work. ACKNOWLEDGEMENTS: The authors thank CTC Communications Corporation (Mississauga, Canada) for professional medical writing support.REFERENCES1. Canadian Cancer Society. Prostate cancer statistics. Accessed July 17, 2024. https://cancer.ca/en/cancer-information/cancer-types/prostate/statistics2. World Cancer Research Fund International. Prostate cancer statistics. Available at: https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/. Accessed July 17, 20243. Shore ND, Moul JW, Pienta KJ, et al. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: Treatment based on risk stratification. Prostate Cancer Prostatic Dis 2023;27:192-201. https://doi.org/10.1038/s41391-023-00712-z4. Schaeffer EM, Srinivas S, Adra N, et al. Prostate cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023;21:1067-96. https://doi.org/10.6004/jnccn.2023.00505. Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2023;389:1453-65. https://doi.org/10.1056/NEJMoa23039746. Aggarwal R, Heller G, Hillman DW, et al. PRESTO: A phase 3, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol 2024;42:1114-23. https://doi.org/10.1200/JCO.23.011577. Beresford MJ, Gillatt D, Benson RJ, et al. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 2010;22:46-55. https://doi.org/10.1016/j.clon.2009.10.0158. De Visschere PJL, Standaert C, F%u00fctterer JJ, et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol 2019;2:47-76. https://doi.org/10.1016/j.euo.2018.09.0109. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185-90. https://doi.org/10.1200/JCO.2010.32.811210. D%u2019Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74. https://doi.org/10.1001/jama.280.11.96911. Virgo KS, Bryan Rumble R, de Wit R, et al. Initial management of non-castrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. J Clin Oncol2021;39:1274-305. https://doi.org/10.1200/JCO.20.0325612. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer. Eur Urol 2021;79:263-82. https://doi.org/10.1016/j.eururo.2020.09.04613. Danielson B, Saad F, So A, et al. Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. Can Urol Assoc J2019;13:420-6. https://doi.org/10.5489/cuaj.560014. Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without shortterm hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): A randomized, multicenter, open-label phase 3 trial. Lancet Oncol 2016;17:747-56. https://doi.org/10.1016/S1470-2045(16)00111-X15. Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol 2024;35:656-66. https://doi.org/10.1016/j.annonc.2024.03.01016. Kneebone A, Fraser-Browne C, Duchesne GM, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): Arandomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2020;21:1331-40. https://doi.org/10.1016/S1470-2045(20)30456-317. Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomized, controlled phase 3 trial. Lancet 2020;396:1413-21. https://doi.org/10.1016/S0140-6736(20)31553-118. Tilki D, Preisser F, Graefen M, et al. External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort. Eur Urol 2019;75:896-900. https://doi.org/10.1016/j.eururo.2019.03.01619. Tseng CS, Wang YJ, Chen CH, et al. Outcomes and prediction models for exclusive prostate bed salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Cancers 2021;13:2672. https://doi.org/10.3390/cancers1311267220. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer%u20132020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79:243-62. https://doi.org/10.1016/j.eururo.2020.09.04221. Siddiqui ZA, Krauss DJ. Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy. Transl Androl Urol 2018;7:378-89. https://doi.org/10.21037/tau.2018.01.0622. Nabid A, Carrier N, Vigneault E, et al. Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomized trials. Radiother Oncol 2024;195:110256. https://doi.org/10.1016/j.radonc.2024.11025623. Van Den Bergh RCN, Van Casteren NJ, Van Den Broeck T, et al. Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: A systematic review. Eur Urol 2016;69:802-20. https://doi.org/10.1016/j.eururo.2015.11.02324. Crook JM, O%u2019Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895-903. https://doi.org/10.1056/NEJMoa120154625. Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6:76-85. https://doi.org/10.1038/ncpuro129626. Dess RT, Sun Y, Jackson WC, et al. Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol 2020;6:735-43. https://doi.org/10.1001/jamaoncol.2020.010927. Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 2017;376:417-28. https://doi.org/10.1056/NEJMoa160752928. Carrie C, Magn%u00e9 N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): A 112-month followup of a phase 3, randomized trial. Lancet Oncol 2019;20:1740-9. https://doi.org/10.1016/S1470-2045(19)30486-329. Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): An international, multicentre, randomized, phase 3 trial. Lancet2022;399:1886-901. https://doi.org/10.1016/S0140-6736(21)01790-630. Valle LF, Lehrer EJ, Markovic D, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol 2021;80:280-92. https://doi.org/10.1016/j.eururo.2020.11.01031. Crook JM, Zhang P, Pisansky TM, et al. A prospective phase 2 trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiation therapy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys 2019;103:335-43. https://doi.org/10.1016/j.ijrobp.2018.09.03932. Fuller D, Wurzer J, Shirazi R, et al. Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: Efficacy and toxicity of HDR-like SBRT. Int J Radiat Oncol Biol Phys 2020;106:291-9. https://doi.org/10.1016/j.ijrobp.2019.10.014287